Skip to content
MedsAcross

Medicine

Ixempra kit

Ixabepilone · R-Pharm US Operating
Available on requestPrescription onlyUS FDA Cold chain

Ixempra kit is a prescription medicine containing Ixabepilone, marketed by R-Pharm US Operating, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.

Availability

Available on request

Export supply from India to licensed buyers

Typical lead time

On request

Counted from payment and complete documents

Shipping

Cold chain

NDC 70020-1910-1 IXEMPRA ® Kit containing one single-dose vial of IXEMPRA ®…

Key facts

Active ingredient (INN)
Ixabepilone
Brand
Ixempra
Dosage form
Kit
Packs
1 kit
Marketing authorisation holder
R-Pharm US Operating
Manufacturer
R-Pharm US Operating
Origin register
US FDA, United States
Storage
NDC 70020-1910-1 IXEMPRA ® Kit containing one single-dose vial of IXEMPRA ® (ixabepilone) for injection, 15 mg and one vial of DILUENT for IXEMPRA, 8 mL NDC 70020-1911 -1 IXEMPRA ® Kit containing one single-dose vial of IXEMPRA ® (ixabepilone) for injection, 45 mg and one vial of DILUENT for IXEMPRA, 23.5 mL IXEMPRA Kit must be stored in a refrigerator at 2° C to 8° C (36° F to 46° F).
Cold chain
Yes, shipped temperature controlled
Prescription status
Prescription only
Controlled substance
Not recorded as controlled
ATC code
L01DC04 Ixabepilone
HS code (indicative)
3004.90Indicative only. Your customs broker confirms the final tariff code.
Marketing category
marketed
Marketed since
16 October 2007
Identifiers
RxCUI 1726271, 1726274, 1726276 +1DailyMed set ID 241f0b1e-8b95-470d-876f-bf1804daaf18NDC 70020-1910Application NDA022065

Record updated 12 November 2026

Documents available

Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.

No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.

Packs

PackCodeLabelerMarketed since
1 kit in 1 package, combination * 15 mg in 1 vial, single-use * 8 mL in 1 vial, single-use70020-1910-1R-Pharm US Operating16 October 2007

Status by register

Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.

RegisterStatusSource
US FDAListed, marketedSource record for this pageChecked 12 November 2026
US FDAFirst approved 16 October 2007Drugs@FDA
EU (EMA)Not recorded—
India (CDSCO)Not yet confirmed against CDSCO approval lists—
United StatesRegisteredUS FDA (NDC directory, openFDA)Checked 12 November 2026

Import route

Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.

Import guides are available for 25 countries. Pick one to see its route summary.

BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides

Alternatives

Other makers and brands of Ixabepilone kit.

Compare 1

Clinical summary

Ixabepilone is a prescription medicine indicated in combination with capecitabine for the treatment of patients with metastatic or locally advanced breast cancer resistant to treatment with an anthracycline and a taxane,, among other approved uses. MedsAcross supplies Ixabepilone for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.

Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review

Read about Ixabepilone

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

Data sources

Need Ixempra kit for your hospital or patient?

Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.

Request a quoteRead the import guides